Peter B. Silverman - 12 Dec 2025 Form 4 Insider Report for Merus N.V. (MRUS)

Role
COO & GC
Signature
/s/ Peter Silverman
Issuer symbol
MRUS
Transactions as of
12 Dec 2025
Net transactions value
$0
Form type
4
Filing time
12 Dec 2025, 19:02:14 UTC
Previous filing
18 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Silverman Peter B. COO & GC C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, NETHERLANDS /s/ Peter Silverman 12 Dec 2025 0001790314

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -50,000 -100% $0.000000 0 12 Dec 2025 Common Shares 50,000 $24.43 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -125,000 -100% $0.000000 0 12 Dec 2025 Common Shares 125,000 $41.65 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -107,300 -100% $0.000000 0 12 Dec 2025 Common Shares 107,300 $36.09 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -3,900 -100% $0.000000 0 12 Dec 2025 Common Shares 3,900 $11.16 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -12,714 -100% $0.000000 0 12 Dec 2025 Common Shares 12,714 $12.37 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -104,000 -100% $0.000000 0 12 Dec 2025 Common Shares 104,000 $16.07 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -20,000 -100% $0.000000 0 12 Dec 2025 Common Shares 20,000 $15.87 Direct F1, F2
transaction MRUS Share Option (right to buy) Disposed to Issuer $0 -83,000 -100% $0.000000 0 12 Dec 2025 Common Shares 83,000 $24.61 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Peter B. Silverman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
F2 This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.